Generic Pharmasec Ltd. Successfully Executes an Order from Reliance Group

Jamnagar/Surat (Gujarat) [India], July 29:  In line with the Company’s strategy to extend Point of Care Diagnostic footprint by focusing on Channel and Dealers network and thereby enhancing its sales turnover, BSE listed M/s Generic Pharmasec Limited (BSE: 531592) has successfully executed order from Reliance Group for upgrading Point of Care Diagnostics by installing Abbot Point of Care I-Stat Blood Analysers at their group hospitals namely, Sir H. N. Reliance Hospital at Mumbai, Reliance Foundation Hospital at Jamnagar, Reliance Industries Hospitals at Bharuch and Surat.

The Company is in dialogue with Reliance Group for further orders and implementation for their Group hospitals at various other locations.

Earlier, the company had also entered into an agreement with Abbott Point of Care (APOC) Inc, the medical & diagnostics devices division of Abbott, the world’s 8th largest Pharma Company, for the distribution, marketing, and promotion of the entire range of products by APOC in India.

The agreement would increase the annual diagnostic tests supplied by Generic Pharmasec Limited by more than two-fold to upwards of 1 million tests annually. It would also improve the Product Margin on the Abbott Point of Care products by Generic Pharmasec by 2.5% which is almost 50% higher than current margins.

Generic Pharmasec Limited would focus on creating high-value propositions for all hospitals in India for all their Critical Diagnostic Requirements. To Increase the footprint in the country & improve access to Critical Diagnostic Solutions in Tier-2 & Tier-3 towns, Generic Pharmasec Limited would appoint 15 new sub-distributors over the course of the next 24 months in such identified towns across the country.

The Company aims to increase i-STAT devices penetration by at least 1,000 additional hospital set-ups in the next 24 months by creating long-term strategies for Marketing & Promotion with this unique partnership with Abbott Point of Care Inc.

Incorporated in 1992, Generic Pharmasec Limited started as a manufacturer and trader of organic and inorganic chemicals, dyes, and pigments. Since 2018, the Company is engaged in the business of buying, selling, and distributing all kinds of pharmaceutical, medicinal, and medicated preparations. The company has decided to shift its core competence to the lucrative medical and diagnostics device segment. Headquartered in Mumbai, the company plans to rapidly expand to all the four major metros within the next 12 months and increase its product portfolio under the said segment over the period of time.

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

Block Beats & Biitca Coin Present Hello Jackpot launching Worldwide on 25/05/2022

May 20: According to DR.SAHIL KADARI, CEO/CMD/Founder of Block Beats Company, blockchain represents the future of the next generation and one of the best investment prospects of our time. He is still investigating the applications and development potential of blockchain technology. He has also received several honours, including the Nelson Mandela Award, Indian Iconic Business […]

Read More
Business

Six Times Failed Revision Hip Replacement Surgery of a Ghana patient performed successfully at Krishna Shalby Hospital, Ahmedabad by World-renowned Joint Replacement Surgeon Dr Vikram Shah

Shalby Team of Doctors sitting from right to left Dr Vikram Shah, Dr J A Pachore, Dr Amish Kshtriya. Standing – Dr Pranay Gujjar May 20: A six times failed hip replacement surgery of a Ghana patient was successfully performed by Dr Vikram Shah, world-renowned joint replacement surgeon, at Krishna Shalby Hospital in Ahmedabad. Besides […]

Read More
Business

Corporate Professionals managing to acquire 26% stake in Advik Capital for Rs 23.75 cr

New Delhi (India), May 20: Corporate Professionals Capital Private Limited is managing to acquire a significant stake in Advik Capital Limited (ACL), the company said in a regulatory filing on 18th May. According to the company filing, Corporate professionals managed to buy 5,72,50,253 equity shares with a face value of Re 1 each at a […]

Read More